Literature DB >> 8540722

Distribution kinetics of enoxacin and its metabolite oxoenoxacin in excretory fluids of healthy volunteers.

U Jaehde1, F Sörgel, K G Naber, J Zürcher, W Schunack.   

Abstract

The distribution kinetics of enoxacin and its main metabolite oxoenoxacin in excretory fluids was investigated in 11 healthy volunteers. A single intravenous dose of 428 mg of enoxacin was given as a 1-h infusion. Serial samples of plasma, urine, saliva, nasal secretions, tears, and sweat were drawn and analyzed for enoxacin and oxoenoxacin by reversed-phase high-pressure liquid chromatography. Large differences in the concentration-time profiles of the excretory fluids analyzed were observed. Nasal secretions exhibited the highest enoxacin exposure, as assessed by the area under the concentration-time curve. Excretory fluid/plasma area under the concentration-time curve ratios were found to be 1.67 +/- 0.36 for nasal secretions, 0.76 +/- 0.28 for saliva, 0.25 +/- 0.07 for sweat, and 0.23 +/- 0.11 for tears. The elimination half-life of enoxacin from sweat (8.27 +/- 2.63 h) was significantly longer than that for plasma (5.10 +/- 0.46 h). Oxoenoxacin was detected in urine and saliva and exhibited a higher renal clearance and a lower saliva exposure than the parent compound. In contrast to that of the metabolite, distribution of enoxacin in saliva was found to be time and pH dependent. In conclusion, our study revealed considerable differences in the distribution kinetics of enoxacin among various excretory sites. Because of distinct acidic and basic properties, the anionic oxometabolite significantly differs from the zwitterionic parent compound in its distribution characteristics.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8540722      PMCID: PMC162887          DOI: 10.1128/AAC.39.9.2092

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

Review 1.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

2.  Pharmacokinetics of three oral formulations of ciprofloxacin.

Authors:  R L Davis; J R Koup; J Williams-Warren; A Weber; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

3.  General principles of antibiotic tissue penetration.

Authors:  M Barza; G Cuchural
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

4.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

5.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

6.  Penetration of ciprofloxacin into parotid gland tissue and parotid saliva.

Authors:  H Maier; A Sziegoleit; S Merck
Journal:  Arzneimittelforschung       Date:  1987-07

7.  Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.

Authors:  T Chang; A Black; A Dunky; R Wolf; A Sedman; J Latts; P G Welling
Journal:  J Antimicrob Chemother       Date:  1988-02       Impact factor: 5.790

8.  Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys.

Authors:  S Nakamura; N Kurobe; S Kashimoto; T Ohue; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

9.  Pharmacokinetics and tissue penetration of enoxacin.

Authors:  R Wise; R Lockley; J Dent; M Webberly
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

10.  Pharmacokinetics: metabolism and renal excretion of quinolones in man.

Authors:  T B Vree; W J Wijnands; P J Guelen; A M Baars; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1986-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.